Professor in Engineering Biology (esp. Cell Engineering)
Johan Hyllner is an international stem cell entrepreneur and researcher and founder of the stem cell company Cellartis (now part of Cellectis International, France). He is adjunct professor at the division since 2012. Since 2013 he is also CSO of the Cell Therapy Catapult in the UK.
Vidarsson H, Johan Hyllner J, and Peter Sartipy P. (2012) Differentiation of human embryonic stem cells to cardiomyocytes for in vitro and in vivo applications. Stem Cell Rev 6, 108-120 (review)
Li O, Tormin A, Sundberg B, Hyllner J, Le Blanc K, Schedling S (2013). Human embryonic stem cell-derived mesenchymal stroma cells (hES-MSCs) engraft in vivo and support hematopoisis without suppressing immune functions: implications for off-the shelf ES-MSC therapies. PLoS ONE 8 (1), e55319
Bisson I, Green E, Sharpe M, Herbert C, Hyllner J, Mount N (2015) Landscape of current and emerging cell therapy clinical trials in the UK: current status, comparison to global trends and future perspectives. Regen. Med. 10, 169-179.
Barry J, Hyllner J, Stacy G, Taylor CJ, Turner M (2015) Settling up a haplobank: issues and solutions. Curr. Stem Cell Rep. DOI 10.1007/s40778-015-0011-7
Responsible for this page: Susanne Andersson
Last updated: 05/22/15